TFF Pharmaceuticals Inc. (TFFP:NASDAQ) announced positive anecdotal data regarding a lung transplant patient treated with its inhaled, dry powder voriconazole, TFF VORI, reported ROTH Capital Partners analyst, Dr. Jonathan Aschoff, in a September 9, 2022, research note.
The life sciences firm is currently trading at $5.31 per share, significantly lower than ROTH's $27 per share price target on it. The difference suggests a significant potential return on investment.
The biopharma is employing its proprietary rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability.
The results shown with this single patient bode well, Aschoff wrote, for the in-progress Phase 2 clinical trial of TFF VORI in nontransplant patients with pulmonary fungal infection. Results, due out later this month, are expected "to underscore the advantages of direct voriconazole administration to the site of action" (i.e.,) the lungs, added Aschoff.
The life sciences firm is currently trading at $5.31 per share, significantly lower than ROTH's $27 per share price target on it. The difference suggests a significant potential return on investment.
The discussed patient, Aschoff relayed, having undergone a bilateral lung transplant due to prior chronic obstructive pulmonary disease, continued getting various pulmonary fungal infections, including Aspergillus. They were treated with various oral antifungals, including voriconazole, but because they caused side effects, the patient could no longer use them.
As part of TFF Pharmaceuticals' ongoing TFF VORI compassionate use program, the patient was given inhaled voriconazole 80 milligrams (80 mg) twice a day plus the antifungal, terbinafine, 200 mg once a day, noted Aschoff. At the time of data collection, the patient had received both drugs for six months.
Over that period, the patient's lung function improved. Their FEV1, or forced expiratory volume in one second, plateaued at 1.6 liters (1.6 l) after having decreased consistently to 1.7 l from 2.98 l prior to the combination treatment. FVC or forced vital capacity, rose to 4.28 l after having dropped to 3.82 l from 4.98 l.
"The patient also had a partial resolution of their scattered nodular foci with bilateral airway-centered ground glass opacification, a measure of increased density in the lungs and thus an indicator of disease," Aschoff wrote.
Further, the patient tolerated TFF VORI well and was able to maintain the same dose of tacrolimus, an immunosuppressant that adversely interacts with oral voriconazole.
ROTH has a Buy rating on TFF Pharmaceuticals.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Disclosures:
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: None. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures For Roth Capital Partners, TFF Pharmaceuticals Inc., September 9, 2022
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Disclosures: ROTH makes a market in shares of TFF Pharmaceuticals, Inc. and as such, buys and sells from customers on a principal basis.
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request.
This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2022. Member: FINRA/SIPC
